MannKind Corporation is a biopharmaceutical company that is focused on the discovery, development and commercialization of therapeutic products for such diseases as diabetes and cancer. The company s lead investigational product candidate, the Technosphere Insulin System, is in Phase 3 clinical trials in the United States, Europe and Latin America to study the safety and efficacy of the system in the treatment of diabetes. The therapy consists of a proprietary dry powder formulation of insulin that is inhaled into the deep lungs using a proprietary inhaler. It features unique kinetics, convenience and ease of use benefits in comparison to other diabetes treatments. MannKind Corporation s research and development activities also span metabolic disorders and oncology. The company s product pipeline includes an active immunotherapy regiment intented for the treatment of several solid tumors, including ovarian, colorectal, pancreatic, renal, breast and prostate carcinomas. It maintains a campus in Danbury, Conn.
Partial Data by Infogroup (c) 2024. All rights reserved.
Partial Data by Foursquare.